Announcing our Partnership with ASM and Rockefeller University Press

Where Biomedical Discovery Starts Now

Something has shifted in how biomedical research gets found…

• Researchers run 10 million biomedical and clinical searches on Consensus every month – half of everything asked on the platform.

• All 20 of the top 20 U.S. research universities have researchers searching on Consensus weekly.

Today, two publishers at the heart of biomedicine – the American Society for Microbiology (ASM) and Rockefeller University Press – are joining the engine behind those numbers. The story of why starts with who's searching.

Those searchers aren't only academics. Clinicians use Consensus at the point of care to see the full evidence on a complex question in seconds. Residents use it to prep for rounds. Biotech scientists use it to scope a target before committing a quarter to it.

They come for the same reason: Consensus reads the full text of the literature, across a comprehensive corpus, and answers with citations you can click, check and trust – no invented references and no summary you have to take on faith.

The Companies Came Next

Over the past year, a second wave arrived: organizations. Some of the world's largest pharmaceutical companies and the sharpest AI-native biotechs are now building on the Consensus API.

Teams are running continuous literature surveillance on targets and safety signals. They're wiring evidence retrieval into AI agents, so an internal model reasons over the current state of the literature instead of a frozen training set. The result: API query volume has grown 1,000% quarter over quarter in 2026.

Every one of those queries requires the same layer underneath: the actual scientific record, at full depth.

Which Is Why Publishers Keep Joining

Today we're announcing partnerships with both ASM and Rockefeller University Press. They join a roster that already includes the likes of Wiley, Taylor & Francis, Sage, Oxford University Press, BMJ, and others – publishers who see what's happening above and recognize it as distribution, in the plural.

Visibility with millions of researchers deciding what to read. Click-through traffic routed to the version of record. And a licensed channel into the enterprise workflows being built on our API – places publisher content has never reached before, on terms publishers set. 

Two Presses, Owned by the Field They Serve

Neither publisher is a commercial house that happens to publish science. One is a scientific society of its own readers, the other a nonprofit university press.

ASM is the field itself, organized. Founded in 1899, tens of thousands of members, sixteen journals holding most of the infrastructure of modern microbiology: the Journal of Bacteriology since 1916, the Journal of Virology, the Journal of Clinical Microbiology, Antimicrobial Agents and Chemotherapy, Infection and Immunity, the mBio family. It’s where the resistance literature lives and where clinical labs validate the assays they actually run. And because ASM is a society, publishing funds the mission rather than the reverse: training, global public health work, capacity building in under-resourced labs, advocacy on antimicrobial resistance. mBio launched fully open access in 2010, ahead of most peers.

For over a century, Rockefeller University Press journals have published groundbreaking research in the life sciences and biomedicine from leading investigators around the world. Established in 1896, Journal of Experimental Medicine published by Oswald T. Avery, Colin M. MacLeod, and Maclyn McCarty’s 1944 discovery that DNA is the molecule holding genetic information.

At a time when the field was just being defined, cell biology researchers formed what would become the Journal of Cell Biology in 1955. Journal of General Physiology, established in 1918, set the stage for the molecular era of electrophysiology research. RUP’s newest publication, Journal of Human Immunity, was established in 2025 as the first journal dedicated to research on human inborn errors of immunity, including primary immunodeficiencies, autoimmunity, autoinflammation, malignancy, and allergy, and is the official journal of the International Alliance for Primary Immunodeficiency Societies (IAPIDS).

At RUP, a longtime policy has been that authors always retain copyright if allowed by their institution and/or funder. Since the early 2000s, RUP has explored and experimented with open access strategies, and today authors can select one of its OA journals or choose to publish immediate OA in the hybrid journals.

Two nonprofits both moving on open access before they had to, both treating the scholarly record as something they hold in trust. Consensus treats it the same way: Partner content is never used to train AI models – it powers search and analysis, and every result is built to send readers to the original work. 

Two Presses, One Question, One Search

Consider a question any infectious disease team recognizes: Why do some patients clear an infection while others don't? The immune biology is in JEM. The pathogen is in the Journal of Virology. The resistance data is in Antimicrobial Agents and Chemotherapy. The assay is in the Journal of Clinical Microbiology. The cell biology of invasion is in JCB.

One question, five journals, two presses. Yesterday that meant five searches in five interfaces. Now it's one – whether it's a clinician typing into Consensus or a pharma pipeline calling the API ten thousand times a night.

And because Consensus indexes the full text, not the abstract, the answer surfaces what specialist literature is actually made of: the isolate, the breakpoint, the model system, the limitation in the discussion section. Papers rank near the top because they're right, not because they're famous.

Try It

The fastest way to see what these partnerships change is to run the question yourself on Consensus. Try "What determines bacterial clearance vs. persistence in chronic infection?" 10 million searches a month suggest researchers already have. And for the organizations building on our API, the record underneath just got deeper.